Friday, March 7th
|
AM

|
|
| 7:00-8:00 |
Breakfast Buffet

|
| 8:00-8:15 |
Welcome and Introduction Ranjan Duara, MD

|
| 8:15-9:15 |
Keynote Address: "What Determines the Risk of and Rate of Progression in Alzheimer's Disease: Mechanisms and Modifiers"
Denis Evans, MD

|
| 9:15-11:15 |
Mini-Symposium: Pathogenic Mechanisms for Cognitive Impairment in Animals and Humans
Chair: Carl Cotman, PhD

|
| |
Amyloid Metabolism and Cognitive Impairment in Animals and Humans Todd Golde, PhD

|
| |
Tau Pathology and Cognitive Impairment in Animals and Humans Karen Duff, PhD

|
| |
Protein Misfolding in the Pathogenesis of AD JoAnne McLaurin, PhD

|
| |
Inflammation and Brain Aging Stephen Bondy, PhD

|
| |
Inflammatory Cytokines and Cognitive Impairment in Aging Philip Wolf, MD

|
| |
Hypertension, Metabolic Syndrome and Cognitive Impairment Jose Luchsinger, MD, MPH

|
| 11:15-11:30 |
Break

|
| 11:30-12:15 |
Open Discussion

|
| 12:15-1:30 |
Lunch Break

|
PM

|
|
| 1:30-4:00 |
Mini-Symposium: Biomarkers for Measuring Progression and the Effects of Treatment in AD
Chair: Mike Weiner, MD

|
| |
Cognitive Measurement Robert Wilson, PhD

|
| |
Volumetric MRI (the ADNI Experience) Clifford Jack, MD

|
| |
4 Tesla MRI in MCI and Early AD Michael Weiner, MD

|
| |
Amyloid Imaging with [C-11] PIB in Normal Aging, MCI and AD Colin Masters, MD, PhD

|
| |
Amyloid Imaging with [F-18] 1, 4-diphenyltriazoles Mike Pontecorvo, PhD

|
| |
PET FDG and Amyloid and Tau Imaging with [F-18] FDDNP in Early AD Gary Small, MD

|
| |
CSF Biomarkers in MCI and Early AD John Morris, MD

|
| 4:00-4:15 |
Break

|
| 4:15-5:00 |
Open Discussion

|
| 5:30-7:00 |
Panel Discussion: Disclosing the Diagnosis: Why, When and How
Chair: Mary Ganguli, MD, MPH
Panelists (Ronald Petersen, MD, PhD; Angela Jefferson, PhD; Mary Mittelman, DrPH; Soo Borson, MD; Eric Rodriguez, MD; Orien Reid, MSW)

|
| 7:00-9:00 |
Welcome Dinner

|
Saturday, March 8th
|
AM

|
|
| 7:30-8:30 |
Breakfast Buffet

|
| 8:30-8:45 |
Announcements and Introductions Ranjan Duara, MD

|
| 8:45-10:30 |
Mini-Symposium: Non-Pharmacological Treatment and Prevention of Early AD and
Other Dementias
Chair: Huntington Potter, PhD

|
| |
Hematopoeitic Growth Factors for Brain Repair Juan Sanchez-Ramos, MD, PhD

|
| |
Risk Factors for Cognitive Decline Laura Fratiglioni, MD, PhD

|
| |
Cognitive and Environmental Stimulation for both Treatment and Prevention of Alzheimer's Disease: Transgenic Mouse Studies Gary Arendash, PhD

|
| |
Cognitive Rehabilitation in MCI and Early AD David Loewenstein, PhD

|
| |
The Role of Exercise and Intellectual Engagement on AD and Cognition of older adults Art Kramer, PhD

|
| 10:30-10:45 |
Break

|
| 10:45-11:30 |
Open Discussion

|
| 11:30-1:00 |
Lunch Break

|
PM

|
|
| 1:00-3:00 |
Mini-Symposium: Potential Disease Modifying Agents for Treatment and Prevention of AD
Chair: Paul Aisen, MD

|
| |
Drug Development for AD and Prodromal AD: an Overview Paul Aisen, MD

|
| |
Clioquinol (Reformulated) Colin Masters, MD

|
| |
Immunotherapy for AD (Immunoglobulin Infusion) Norman Relkin, MD, PhD

|
| |
Immunotherapy for AD (Antibody Infusion) Michael Grundman, MD

|
| |
Flurizan: A Gamma Secretase Modulating Agent Kenton Zavitz, PhD

|
| |
LY450139: a Gamma secretase inhibitor Eric Siemers, MD, PhD

|
| 3:00-3:15 |
Break

|
| 3:15-4:00 |
Open Discussion

|
| 4:00 |
Adjourn

|